We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+12.53%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.25B
AUM Growth
+$307M
Cap. Flow
+$95.8M
Cap. Flow %
2.95%
Top 10 Hldgs %
41.75%
Holding
101
New
19
Increased
28
Reduced
23
Closed
18

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$68.6M
2
ALLK
Allakos
ALLK
+$59.9M
3
WMGI
Wright Medical Group Inc
WMGI
+$58.6M
4
FATE icon
Fate Therapeutics
FATE
+$43.8M
5
REPL icon
Replimune Group
REPL
+$38.4M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$60.7M
2
WCG
Wellcare Health Plans, Inc.
WCG
+$56.5M
3
LH icon
Labcorp
LH
+$51.8M
4
INSM icon
Insmed
INSM
+$48.1M
5
CNC icon
Centene
CNC
+$39.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.24%
2 Miscellaneous 1.57%
3 Financials 1.28%
4 Energy 0.69%
5 Technology 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NITE
26
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$42.5M 1.31%
2,080,846
+295,400
+17% +$6.06M
XERS icon
27
Xeris Biopharma Holdings
XERS
$1.55B
$42.4M 1.3%
2,412,640
-2
-0% -$43
EHTH icon
28
eHealth
EHTH
$38.4M
$41.6M 1.28%
1,472,595
+94,700
+7% +$2.51M
HSKA
29
DELISTED
Heska Corp
HSKA
$41M 1.26%
361,676
+6,900
+2% +$725K
UNH icon
30
UnitedHealth
UNH
$353B
$38.8M 1.19%
145,820
+2,800
+2% +$728K
BLUE
31
DELISTED
bluebird bio
BLUE
$36.8M 1.13%
19,462
-1,266
-6% -$2.62M
OXFD
32
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$36.3M 1.12%
2,235,407
+200
+0% +$2.86K
REPL icon
33
Replimune Group
REPL
$1.46B
$35.3M 1.09%
+2,192,957
New +$38.4M
CBAY
34
DELISTED
Cymabay Therapeutics
CBAY
$33.2M 1.02%
2,993,565
+35,800
+1% +$445K
PEN icon
35
Penumbra
PEN
$12.7B
$32.5M 1%
217,129
+144,959
+201% +$20.3M
CNC icon
36
Centene
CNC
$32B
$32.1M 0.99%
443,490
-572,480
-56% -$39.7M
GRTS
37
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$31.9M 0.98%
+2,242,636
New +$31.9M
NUVA
38
DELISTED
NuVasive, Inc.
NUVA
$31.2M 0.96%
+439,700
New +$28M
CVS icon
39
CVS Health
CVS
$119B
$31M 0.95%
+394,300
New +$28.2M
CTLT
40
DELISTED
CATALENT, INC.
CTLT
$30.5M 0.94%
668,850
+7,000
+1% +$296K
CBIO
41
Crescent Biopharma
CBIO
$659M
$29.5M 0.91%
20,481
+188
+0.9% +$284K
TDOC icon
42
Teladoc Health
TDOC
$1.18B
$28.9M 0.89%
334,700
+103,700
+45% +$7.39M
PRQR icon
43
ProQR Therapeutics
PRQR
$323M
$28.1M 0.86%
+1,450,925
New +$15.4M
MOR
44
DELISTED
MorphoSys AG American Depositary Shares
MOR
$24M 0.74%
899,900
-369,900
-29% -$11.1M
EPZM
45
DELISTED
Epizyme, Inc
EPZM
$23.8M 0.73%
2,248,189
+226,800
+11% +$2.59M
ZTS icon
46
Zoetis
ZTS
$32B
$23.2M 0.71%
253,300
+4,200
+2% +$373K
LHCG
47
DELISTED
LHC Group LLC
LHCG
$22.4M 0.69%
+217,480
New +$20.3M
SYNH
48
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$22.1M 0.68%
428,473
-553,200
-56% -$27.1M
PRAH
49
DELISTED
PRA Health Sciences, Inc.
PRAH
$22M 0.68%
+200,000
New +$20.8M
A icon
50
Agilent Technologies
A
$43.4B
$21.6M 0.66%
+306,400
New +$20.3M
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2018 Portfolio in Review

As of Q3 2018, Redmile Group held 101 positions worth $3.25B, up 10% from $2.94B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group's Q3 2018 filing shows 19 new, 28 increased, 23 reduced and 18 closed positions. Its largest new stake was Cigna: 370,200 shares worth $77.1M. The largest sale was Alexion Pharmaceuticals, an estimated $60.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q3 2018 buy was Cigna: 370,200 shares worth $77.1M.
  • Redmile Group added most to Fate Therapeutics in Q3 2018, an estimated $43.8M increase.
  • Redmile Group's biggest Q3 2018 reduction was Wellcare Health Plans, Inc., cutting an estimated $56.5M.
  • Redmile Group fully exited Alexion Pharmaceuticals in Q3 2018, selling an estimated $60.7M.
  • Redmile Group's ten largest holdings make up 42% of its $3.25B portfolio in Q3 2018.
  • Redmile Group opened 19 new positions and closed 18 in Q3 2018.
  • Redmile Group's portfolio value rose 10% quarter-over-quarter to $3.25B.

Based on Redmile Group's 13F filing for Q3 2018, filed 14 Nov 2018.